We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SHEL:LSEShell Plc Analysis

Data as of 2026-06-06 - not real-time

£3,227.50

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Shell trades at £3,227, roughly 12% above its DCF‑derived fair value of £2,885. The stock’s forward P/E of 8.9 contrasts sharply with the sector average of 22, suggesting a valuation discount. A dividend yield of 3.6% and a payout ratio near 45% underline strong cash‑return capacity. Low‑beta (‑0.23) and a 30‑day volatility of 22% indicate modest market correlation but notable price swings. Technicals show a neutral trend, with the 20‑day SMA below price, a bullish MACD histogram, and an RSI hovering at 50, implying no immediate over‑bought pressure.
Q1 2026 results delivered adjusted EPS of $2.44, beating consensus, yet revenue slipped to $69.7 bn versus the $81 bn forecast. The earnings beat was offset by a rise in net debt to $75.6 bn and a scaled‑back share‑buyback program. Management announced an interim dividend of $0.3906 per share, reinforcing the attractive yield. The mixed earnings narrative, combined with solid free cash flow of $15.6 bn, supports the dividend but flags pressure on leverage. Consequently, while the stock appears slightly overvalued on price, its cash flow and dividend profile remain compelling for income‑focused investors.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Mixed earnings with revenue miss
  • Higher dividend reinforces yield
  • Technical MACD bullish but price near support

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Attractive dividend yield and payout ratio
  • Low forward P/E vs industry
  • Strong free cash flow generation

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Regulatory and energy‑transition risk
  • Diversification into renewables and low‑carbon solutions
  • Valuation appears slightly overvalued relative to DCF

Key Metrics & Analysis

Financial Health

Revenue Growth0.70%
Profit Margin7.01%
P/E Ratio13.5
ROE10.70%
ROA4.99%
Debt/Equity43.32
P/B Ratio1.4
Op. Cash Flow£39.6B
Free Cash Flow£15.6B
Industry P/E22.1

Technical Analysis

TrendNeutral
RSI50.5
Support£3,078.00
Resistance£3,758.50
MA 20£3,192.88
MA 50£3,299.76
MA 200£2,934.40
MACDBullish
VolumeIncreasing
Fear & Greed Index83.02

Valuation

Fair Value£2,884.74
Target Price£3,909.16
Upside/Downside21.12%
GradeOvervalued
TypeValue
Dividend Yield3.60%

Risk Assessment

Beta-0.23
Volatility22.06%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.